MuirheadN., BargmanJ., BurgessE.Evidence-based recommendations for the clinical use of recombinant human erythropoietin.Am J Kidney Dis1995; 26(Suppl 1): Sl–24.
2.
US Renal Data System.USRDS 1991 annual report.The National Institute of Health, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland, 1991.
FoleyR.N., ParfreyP.S., HarnettJ.D.Clinical and echo cardiographic disease in patients starting endstage renal disease therapy.Kidney Int1995; 47: 18692.
5.
HarnettJ.D., FoleyR.N., KentG.M., BarreP.E., MurrayD.Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.Kidney Int1995; 47: 884–90.
6.
FoleyR.N., ParfreyP.S., HarnettJ.D., KentG.M., MurrayD.C., BarreP.E.The prognostic importance of left ventricular geometry in uremic cardiomyopathy.J Am Soc Nephrol1995; 5: 2024–31.
7.
ParfreyP.S., FoleyR.N., HarnettJ.D., KentG.M., MurrayD.C., BarreP.E.Outcome and risk factors for left ventricular disorders in chronic uremia.Nephrol Dial Transplant1996; 11: 1277–85.
8.
HarnettJ.D., KentG.M., FoleyR.N., ParfreyP.S.Cardiac function and hematocrit levels.Am J Kidney Dis1995; 25(Suppl 1): S3–7.
9.
FoleyR.N., ParfreyP.S., HarnettJ.D., KentG.M., MurrayD.C., BarreP.E.The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease.Am J Kidney Dis1996; 28: 62–6.
10.
BajoM.A., SelgasR., CastroM.J.Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients.PeTit Dial Int1997; 17: 129–35.
